Pritelivir: Who Can Receive the Newly Approved Drug?
Source announcement: . Published by iMedic on October 10, 2026.
Quick Facts
Key takeaways
- The indication is narrower than routine cold-sore care.
- Lesion healing does not mean HSV has been eliminated.
Who does the approval cover?
The FDA announcement lists prior nonresponse to acyclovir, valacyclovir or famciclovir. Eligibility therefore involves more than simply having HSV.
How well did it work in the trial?
The randomized, open-label PRIOH-1 comparison used investigator-selected treatments as the control. The difference is 29 percentage points, calculated from the reported proportions. That is an absolute difference in this trial, not a guarantee for a future patient.
What limits and safety issues matter?
HSV can persist after lesions heal. Headache was the most common adverse reaction reported by the FDA, which also directs clinicians to drug-interaction information. A clinician should review other medicines before selecting treatment.
Frequently Asked Questions
No.
No; the indication is restricted.
Yes, immunocompromised adults.
Complete lesion healing during treatment through day 28.
Only after review with their treating clinician.
References
- FDA Hovilpri approval summary. Source checked October 10, 2026.
- FDA dated drug-news listing. Source checked October 10, 2026.
How was this news summary prepared?
iMedic Editorial Team checked this summary against the primary sources linked above. It reports a dated announcement and its limitations; it is not an individual treatment recommendation. Editorial standards.